SANUWAVE Health Inc

In a Stage 4 decline, both medium- and long-term biases remain bearish. Despite an extreme oversold bounce, price is still below the downward-sloping 9/21 EMAs without any clear rejection at resistance levels. With no definitive short-side trigger, execution should be deferred, awaiting a pullback into the EMA zone for a structurally sound short entry.

• ↑UltraMist system taps growing wound care demand and rising consumable sales
• ↑Low debt supports sustained R&D and marketing investments
• ↓Q2 revenue $9.6–$9.8M fell 3–5% from prior year